Related Experiment Videos
The endoperoxides/TxA2 analogue, U46619, inhibits human polymorphonuclear leukocyte function
S Rotondo1, A Celardo, V Evangelista
1Istituto di Ricerche Farmacologiche Mario Negri, G. Bizzozero Laboratory of Platelet and Leukocyte Pharmacology, Santa Maria Imbaro, Italy.
Journal of Leukocyte Biology
|January 1, 1995
Summary
Thromboxane A2 analogue U46619 inhibits polymorphonuclear leukocyte (PMN) functions like aggregation and enzyme release. This suggests prostaglandin endoperoxides modulate inflammatory cell activities.
Area of Science:
- Immunology
- Inflammation Research
- Cellular Biology
Background:
- Polymorphonuclear leukocytes (PMNs) are key immune cells involved in inflammatory responses.
- Thromboxane A2 (TxA2) is a potent mediator of inflammation and platelet aggregation.
- Understanding how TxA2 analogues affect PMN function is crucial for inflammatory disease research.
Purpose of the Study:
- To investigate the effects of the stable TxA2 analogue, U46619, on various functions of human polymorphonuclear leukocytes (PMNs).
- To elucidate the specific mechanisms by which U46619 modulates PMN activation and mediator release.
Main Methods:
- PMN aggregation, beta-glucuronidase release, and superoxide production were measured following stimulation with formyl-methionyl-leucyl-phenylalanine (fMLP) or calcium ionophore A23187.
- Intracellular calcium ([Ca2+]) levels were monitored using Fura-2.
- Leukotriene B4 (LTB4) synthesis and arachidonic acid (AA) release were analyzed.
- Comparison with a 5-lipoxygenase inhibitor (L-663,536) and a phospholipase A2 inhibitor (manoalide) was performed.
Main Results:
- U46619 inhibited fMLP-stimulated PMN aggregation, beta-glucuronidase release, superoxide production, and LTB4 synthesis.
- U46619 did not affect fMLP-induced intracellular calcium increase.
- U46619 inhibited aggregation, beta-glucuronidase release, superoxide anion, and LTB4 production induced by A23187.
- U46619 reduced the release of free arachidonic acid from membrane phospholipids.
- U46619's effect on beta-glucuronidase release was similar to that of manoalide.
Conclusions:
- U46619 inhibits PMN activation downstream of initial calcium signaling.
- The inhibitory effects of U46619 are likely due to interference with arachidonic acid release from membrane phospholipids, potentially via phospholipase A2.
- Prostaglandin endoperoxides may play a significant role in modulating PMN activities during inflammation.